Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: A retrospective study

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Hong, Chao Qun ^a   Zhang, Fan ^a   You, Yan Jie ^b   Qiu, Wei Li ^a   Giuliano, Armando E ^c   Cui, Xiao Jiang ^c   Zhang, Guo Jun ^a   Cui, Yu Kun ^a  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b Luohe Medical College   (China)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

C1orf63; CDK10; Overall survival; TNM stage

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; C1ORF63 PROTEIN, HUMAN; CDK10 PROTEIN, HUMAN; PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 1; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG CANCER; MICROARRAY ANALYSIS; OPEN READING FRAME; OVERALL SURVIVAL; PREDICTION; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RNA SEQUENCE; SEQUENCE ANALYSIS; SURVIVAL RATE; WESTERN BLOTTING; ADULT; AGED; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84937936336     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1569-2     Document Type: Article

References (43)

1. Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr. 2000;27:17-37.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
3. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1-10.
4. Henrich KO, Schwab M, Westermann F. 1p36 tumor suppression--a matter of dosage? Cancer Res. 2012;72:6079-88.
5. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer. 1999;79:1468-74.
6. Utada Y, Emi M, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, et al. Allelic loss at 1p34-36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res. 2000;6:3193-8.
7. Munn KE, Walker RA, Varley JM. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene. 1995;10:1653-7.
8. Chechlinska M, Siwicki JK, Gos M, Oczko-Wojciechowska M, Jarzab M, Pfeifer A, et al. Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal. BMC Genomics. 2009;10:261.
9. Heller G, Ziegler B, Brandstetter A, Novak S, Rudas M, Hennig G, et al. CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res. 2009;29:3939-44.
10. Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong Q, Tai S, et al. CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep. 2012;27:1266-76.
11. Hwang SB, Bae JW, Lee HY, Kim HY. Circulating tumor cells detected by RT-PCR for CK-20 before surgery indicate worse prognostic impact in triple-negative and HER2 subtype breast cancer. J Breast Cancer. 2012;15:34-42.
12. Patel RM, Folpe AL. Immunohistochemistry for human telomerase reverse transcriptase catalytic subunit (hTERT): a study of 143 benign and malignant soft tissue and bone tumours. Pathology. 2009;41:527-32.
13. Han YP, Ma CK, Wang SQ, Enomoto A, Zhao Y, Takahashi M, et al. Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors. J Neurooncol. 2014;119(2):343-51.
14. Pau Ni IB, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Aina Emran N, et al. Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. Pathol Res Pract. 2010;206:223-8.
15. Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;34:2300-8.
16. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66:10292-301.
17. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, et al. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer. 2008;122:1324-32.
18. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103:264-72.
19. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529-41.
20. Yap YL, Lam DC, Luc G, Zhang XW, Hernandez D, Gras R, et al. Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids Res. 2005;33:409-21.
21. Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, et al. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev. 2010;19:2590-7.
22. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68:927-36.
23. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790-9.
24. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 2009;15:85-94.
25. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938-47.
26. Sirbu A, Kerr G, Crane M, Ruskin HJ. RNA-Seq vs dual- and single-channel microarray data: sensitivity analysis for differential expression and clustering. PLoS One. 2012;7:e50986.
27. Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241.
28. Rao PH, Roberts D, Zhao YJ, Bell D, Harris CP, Weber RS, et al. Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res. 2008;14:5181-7.
29. Puerto S, Marcos R, Ramirez MJ, Galofre P, Creus A, Surralles J. Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine. Mutat Res. 2000;469:147-58.
30. Egeli U, Ozkan L, Tunca B, Kahraman S, Cecener G, Ergul E, et al. The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites. Head Neck. 2000;22:591-8.
31. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, et al. Characterization of chromosome 1 abnormalities in malignant melanomas. Genes Chromosomes Cancer. 2000;28:121-5.
32. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene. 2008;27:803-10.
33. Takita J, Chen Y, Okubo J, Sanada M, Adachi M, Ohki K, et al. Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. Cancer Sci. 2011;102:1645-50.
34. Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin. 2010;31:1165-71.
35. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005;24:4741-53.
36. Rolland T, Tasan M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, et al. A proteome-scale map of the human interactome network. Cell. 2014;159:1212-26.
37. Nam SY, Seo HH, Park HS, An S, Kim JY, Yang KH, et al. Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation. J Biol Chem. 2010;285:31157-63.
38. Kullo IJ, Ding K, Shameer K, McCarty CA, Jarvik GP, Denny JC, et al. Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate. Am J Hum Genet. 2011;89:131-8.
39. Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, et al. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. BMC Cancer. 2013;13:178.
40. Meng X, Zhang Q, Zheng G, Pang R, Hua T, Yang S, et al. Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice. Oncol Lett. 2014;7:2053-8.
41. Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. BMC Cancer. 2013;13:363.
42. Fregoso OI, Das S, Akerman M, Krainer AR. Splicing-factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. Mol Cell. 2013;50:56-66.
43. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 2008;13:91-104.